A Phase Ib/II Study of OMP-59R5 plus Etoposide and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer

Protocol
13-125
Full Title
A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer
Phase
I/II
Purpose

Etoposide and cisplatin are two drugs commonly used to treat extensive stage small cell lung cancer (ES-SCLC). In this study, researchers want to find the highest dose of an investigational drug called OMP-59R5 that can be given safely with etoposide and cisplatin in patients with ES-SCLC, and to evaluate the preliminary effectiveness of this drug combination.

OMP-59R5 is an antibody that binds to a particular molecule on tumor cells and may block the growth of early small cell lung cancer cells. OMP-59R5, etoposide, and cisplatin are all given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have newly diagnosed, previously untreated ES-SCLC.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is open to patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. M. Catherine Pietanza at 646-888-4203.

Disease(s)
Lung Cancer, Small Cell: Other
Locations